ArticleMolecular and cellular biology1997
Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.
Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 171 citations in OpenAlex.
- Inhibin subunit beta B (INHBB): an emerging role in tumor progression.Journal of physiology and biochemistry · 2024Review
- Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer.Cancer medicine · 2024Article
- Evolving roles of activins and inhibins in ovarian cancer pathophysiology.American journal of physiology. Cell physiology · 2023Review
- Genetic analysis of activin/inhibin β subunits in zebrafish development and reproduction.PLoS genetics · 2022Article
- Low expression of INHB co-receptor TGFBR3 in connection with metastasis and immune infiltration in lung adenocarcinoma.American journal of translational research · 2022Article
- Receptor binding competition: A paradigm for regulating TGF-β family action.Cytokine & growth factor reviews · 2021Review
- E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression.International journal of molecular sciences · 2021Review
- The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.Endocrinology · 2019Review
- The Activin Receptor, Activin-Like Kinase 4, MediatesFrontiers in cellular and infection microbiology · 2019Article
- VWC2 Increases Bone Formation Through Inhibiting Activin Signaling.Calcified tissue international · 2018Article
- The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro.Cellular and molecular neurobiology · 2018Article
- Activin in acute pancreatitis: Potential risk-stratifying marker and novel therapeutic target.Scientific reports · 2017Article
- Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.The Journal of biological chemistry · 2016Article
- Ascending the PEAK1 toward targeting TGFβ during cancer progression: Recent advances and future perspectives.Cancer cell & microenvironment · 2016Article
- TGFβ signaling promotes juvenile granulosa cell tumorigenesis by suppressing apoptosis.Molecular endocrinology (Baltimore, Md.) · 2014Article
- Inhibin at 90: from discovery to clinical application, a historical review.Endocrine reviews · 2014Review
- Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.Molecular & cellular proteomics : MCP · 2013Article
- Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis.FEBS letters · 2012Review
- Phospho-specific Smad3 signaling: impact on breast oncogenesis.Cell cycle (Georgetown, Tex.) · 2012Review
- Neuroendocrine control of FSH secretion: IV. Hypothalamic control of pituitary FSH-regulatory proteins and their relationship to changes in FSH synthesis and secretion.Biology of reproduction · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Activins and inhibins belong to the transforming growth factor beta (TGF-beta)-like superfamily and exert their effects on a broad range of cellular targets by modulating cell differentiation and proliferation. Members of this family interact with two structurally related classes of receptors (type I and type II), both containing a serine/threonine kinase domain. When expressed alone, the type II but not the type I activin receptor can bind activin. However, the presence of a type I receptor is required for signaling. For TGF-beta1, ligand binding to the type II receptor results in the recruitment and transphosphorylation of the type I receptor. Transient overexpression of the two types of activin receptor results in ligand-independent receptor heteromerization and activation. Nevertheless, activin addition to the transfected cells increased complex formation between the two receptors, suggesting a mechanism of action similar to that observed for the TGF-beta receptor. In the present study, we generated a stable cell line, overexpressing the two types of activin receptor upon induction, in the human erythroleukemia cell line K562. We demonstrate here that activin specifically induces heteromer formation between the type I and type II receptors in a time-dependent manner. Using this stable line, we analyzed the effects of activin and inhibin on human erythroid differentiation. Our results indicate that activin signal transduction mediated through its type I and type II receptors results in an increase in the hemoglobin content of the cells and limits their proliferation. Finally, using cell lines that can be induced to overexpress ActRII and ActRIB or ActRIB only, we show that the inhibin antagonistic effects on activin-induced biological responses are mediated through a competition for the type II activin receptor but also require the presence of an inhibin-specific binding component.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.